<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80629">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925547</url>
  </required_header>
  <id_info>
    <org_study_id>0315679-HS3</org_study_id>
    <nct_id>NCT01925547</nct_id>
  </id_info>
  <brief_title>Micellar Curcumin and Metabolic Syndrome Biomarkers</brief_title>
  <official_title>Effect of Micellar Curcumin on Inflammation and Lipid Metabolism Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hohenheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of micellar curcumin on inflammation
      and lipid metabolism markers in subjects at risk for the metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum CRP in mg/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma curcumin concentrations</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations (in nmol/L) of curcumin and curcumin conjugates in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase activity</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum activity of ALT in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting blood glucose in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma tumor necrosis factor alpha</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations of TNFα in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum concentrations of uric acid in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma albumin</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma concentrations of albumin in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum total cholesterol in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum triacylglycerols in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum HDL cholesterol in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum LDL cholesterol in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum aspartate transaminase activity</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum activity of AST in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gamma glutamyl transferase activity</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum activity of gamma-GT in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alkaline phosphatase activity</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum activity of ALP in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum concentrations of bilirubin in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma interleukine 6</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations of IL-6 in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum concentrations of insulin in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body weight in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diastolic blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum concentrations of creatinine in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Systolic blood pressure in mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Metabolic Syndrome, Protection Against</condition>
  <arm_group>
    <arm_group_label>Micellar curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Micellar curcumin</intervention_name>
    <description>80 mg micellar curcumin (oral) three times a day for six weeks</description>
    <arm_group_label>Micellar curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Total cholesterol &gt; 5.2 mmol/L

          -  LDL cholesterol &gt; 3.4 mmol/L

          -  Triglyceride &gt; 2.26 mmol/L

          -  CRP &gt; 2 mg/L

        Exclusion criteria:

          -  Intake of drugs or dietary supplements

          -  Pregnant women and breastfeeding mothers

          -  Smokers

          -  Previous illnesses such as heart attack, cancer or dementia

          -  Addiction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Frank, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hohenheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Biological Chemistry and Nutrition, University of Hohenheim</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>July 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hohenheim</investigator_affiliation>
    <investigator_full_name>Jan Frank</investigator_full_name>
    <investigator_title>Professor, Ph.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
